Pancreatic Adenocarcinoma — Trials

Pancreatic Adenocarcinoma — Trials · CancerIndex

Clinical trials

Registered studies

915 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 356
Recruiting: 209
Ph III recruiting: 23
Growth YoY: +41.4%
Industry share: 41%
Top sponsor: National Cancer Institute (NCI)
Termination share: 38.1%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (136)

clinicaltrialsPublishedShowing 1–50 of 375 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04548752	Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations	active not recruiting	Phase 2	88	National Cancer Institute (NCI)NIH	1	Sep 29, 2026	clinicaltrials
NCT04605913	Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC	active not recruiting	Phase 1 / Phase 2	40	Mayo ClinicOTHER	1	Sep 29, 2026